Recent attempts of treatment for unresectable or metastatic disease comprise targeted therapies against the epidermal growth factor receptor (EGFR, ErbB1) and the human epidermal growth factor receptor 2 (HER2, ErbB2) (Haddad et al, 2003; Agulnik et al, 2007; Locati et al, 2008). This evidence concerns the gene EGFR and metastatic neoplasm.